SEC Filings
State Street Holds 4.4% Of Replimune Common Stock In Passive Position
The September 30 holding comprised 4,174,260 shares, with State Street certifying it was not held to influence control.
Replimune Group (REPL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The September 30 holding comprised 4,174,260 shares, with State Street certifying it was not held to influence control.
Markets
The cancer-drug developer reported a $57.1 million quarterly net loss and said more than 15 institutions are prescribing Tudriqev.
Earnings
The cancer drugmaker's executives described a fast first three weeks and a nearly fully staffed sales team.
Earnings
Executives cited about 20 accounts on formulary and a $450,000 list price per course, with no first product revenue until next quarter.
SEC Filings
The cancer-drug developer's debt covenant offers three ways to pass as its first product, TUDRIQEV, reaches patients.
SEC Filings
The melanoma drug maker says it holds over a year of inventory and cash to fund operations for more than twelve months.